N. Turner, G. J. Cooney, E. W. Kraegen, and C. R. Bruce, Fatty acid metabolism, energy expenditure and insulin resistance in muscle, J endocrinol, vol.220, pp.61-79, 2014.

Q. G. Karwi, G. M. Uddin, K. L. Ho, and G. D. Lopaschuk, Loss of metabolic flexibility in the failing heart, Front Cardiovasc Med, vol.5, p.68, 2018.

V. Lionetti, W. C. Stanley, and F. A. Recchia, Modulating fatty acid oxidation in heart failure, Cardiovasc Res, vol.90, pp.202-211, 2011.

J. Bastin, Regulation of mitochondrial fatty acid beta-oxidation in human: what can we learn from inborn fatty acid beta-oxidation deficiencies?, Biochimie, vol.96, pp.113-133, 2014.

W. Fan and R. Evans, PPARs and ERRs: molecular mediators of mitochondrial metabolism, Curr Opin Cell Biol, vol.33, pp.49-54, 2015.

M. T. Nakamura, B. E. Yudell, and J. J. Loor, Regulation of energy metabolism by longchain fatty acids, Prog Lipid Res, vol.53, pp.124-168, 2014.

L. Rui, Energy metabolism in the liver, Compr Physiol, vol.4, pp.177-97, 2014.

L. Zhang, W. Keung, and V. Samokhvalov, Role of fatty acid uptake and fatty acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle, Biochim Biophys Acta, vol.1801, pp.1-22, 2010.

R. Fucho, N. Casals, D. Serra, and L. Herrero, Ceramides and mitochondrial fatty acid oxidation in obesity, FASEB J, vol.31, pp.1263-72, 2017.

G. Aubert, R. B. Vega, and D. P. Kelly, Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart, Biochim Biophys Acta, vol.1833, pp.840-847, 2013.

K. J. Menzies, H. Zhang, E. Katsyuba, and J. Auwerx, Protein acetylation in metabolism: metabolites and cofactors, Nat Rev Endocrinol, vol.12, pp.43-60, 2016.

M. Knobloch, G. A. Pilz, and B. Ghesquiere, A fatty acid oxidation-dependent metabolic shift regulates adult neural stem cell activity, Cell Rep, vol.20, pp.2144-55, 2017.

Z. Xie, A. Jones, and J. T. Deeney, Inborn errors of long-chain fatty acid betaoxidation link neural stem cell self-renewal to autism, Cell Rep, vol.14, pp.991-1000, 2016.

A. Carracedo, L. C. Cantley, and P. P. Pandolfi, Cancer metabolism: fatty acid oxidation in the limelight, Nat Rev Cancer, vol.13, pp.227-259, 2013.

F. Djouadi, F. Aubey, D. Schlemmer, and J. Bastin, Peroxisome proliferator activated receptor delta (PPAR?) agonist but not PPAR alpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells, J Clin Endocrinol Metab, vol.90, pp.1791-1798, 2005.

M. B. Gillingham, S. B. Heitner, and J. Martin, Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial, J Inherit Metab Dis, vol.40, pp.831-874, 2017.

M. B. Gillingham, C. O. Harding, and D. A. Schoeller, Altered body composition and energy expenditure but normal glucose tolerance among humans with a long-chain fatty acid oxidation disorder, Am J Physiol Endocrinol Metab, vol.305, pp.1299-308, 2013.

A. Mansouri, C. H. Gattolliat, and T. Asselah, Mitochondrial dysfunction and signaling in chronic liver diseases, Gastroenterology, vol.155, pp.629-676, 2018.

D. H. Ipsen, J. Lykkesfeldt, and P. Tveden-nyborg, Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease, Cell Mol Life Sci, vol.75, pp.3313-3340, 2018.

V. Ratziu, S. A. Harrison, and S. Francque, Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening, Gastroenterology, vol.150, pp.1147-59, 2016.

O. Pougovkina, H. Te-brinke, and R. Ofman, Mitochondrial protein acetylation is driven by acetyl-CoA from fatty acid oxidation, Hum Mol Genet, vol.23, pp.3513-3535, 2014.

E. Mcdonnell, S. B. Crown, and D. B. Fox, Lipids reprogram metabolism to become a major carbon source for histone acetylation, Cell Rep, vol.17, pp.1463-72, 2016.

I. Tein, Impact of fatty acid oxidation disorders in child neurology: from Reye syndrome to Pandora's box, Dev Med Child Neurol, vol.57, pp.304-310, 2015.

R. Barone, S. Alaimo, and M. Messina, A subset of patients with autism spectrum disorders show a distinctive metabolic profile by dried blood spot analyses, Front Psychiatry, vol.9, p.636, 2018.

T. Tyni, A. Paetau, and A. W. Strauss, Mitochondrial fatty acid beta-oxidation in the human eye and brain: implications for the retinopathy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, PediatrRes, vol.56, pp.744-50, 2004.

J. N. Jernberg, C. E. Bowman, M. J. Wolfgang, and S. Scafidi, Developmental regulation and localization of carnitine palmitoyltransferases (CPTs) in rat brain, J Neurochem, vol.142, pp.407-426, 2017.

A. Panov, Z. Orynbayeva, V. Vavilin, and V. Lyakhovich, Fatty acids in energy metabolism of the central nervous system, Biomed Res Int, p.472459, 2014.

L. Pei and D. C. Wallace, Mitochondrial etiology of neuropsychiatric disorders, Biol Psychiatry, vol.83, pp.722-752, 2018.

S. M. Houten, S. Violante, F. V. Ventura, and R. J. Wanders, The biochemistry and physiology of mitochondrial fatty acid beta-oxidation and its genetic disorders, Annu Rev Physiol, vol.78, pp.23-44, 2016.

J. P. Bonnefont, F. Djouadi, and C. Prip-buus, Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects, Mol Aspects Med, vol.25, pp.495-520, 2004.

N. Casals, V. Zammit, and L. Herrero, Carnitine palmitoyltransferase 1C: from cognition to cancer, Prog Lipid Res, vol.61, pp.134-182, 2016.

M. Chegary, H. Brinke, and J. P. Ruiter, Mitochondrial long chain fatty acid beta-oxidation in man and mouse, Biochim Biophys Acta, vol.1791, pp.806-821, 2009.

B. Fould, V. Garlatti, and E. Neumann, Structural and functional characterization of the recombinant human mitochondrial trifunctional protein, Biochemistry, vol.49, pp.8608-8625, 2010.

J. Baruteau, P. Sachs, and P. Broue, Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study of 187 patients, J Inherit Metab Dis, vol.36, pp.795-803, 2013.

S. Knottnerus, J. C. Bleeker, and R. Wust, Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle, Rev Endocr Metab Disord, vol.19, pp.93-106, 2018.

S. E. Olpin, Pathophysiology of fatty acid oxidation disorders and resultant phenotypic variability, J Inherit Metab Dis, vol.36, pp.645-58, 2013.

U. Spiekerkoetter, J. Bastin, and M. Gillingham, Current issues regarding treatment of mitochondrial fatty acid oxidation disorders, J Inherit Metab Dis, vol.33, pp.555-61, 2010.

P. Janeiro, R. Jotta, and R. Ramos, Follow-up of fatty acid beta-oxidation disorders in expanded newborn screening era, Eur J Pediatr, vol.178, pp.387-94, 2019.

J. Vockley, J. Charrow, and J. Ganesh, Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders, Mol Genet Metab, vol.119, pp.223-254, 2016.

J. Vockley, D. Marsden, and E. Mccracken, Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review, Mol Genet Metab, vol.116, pp.53-60, 2015.

D. Abdurrachim, J. J. Luiken, and K. Nicolay, Good and bad consequences of altered fatty acid metabolism in heart failure: evidence from mouse models, Cardiovasc Res, vol.106, pp.194-205, 2015.

N. Fillmore, J. Mori, and G. D. Lopaschuk, Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy, Br J Pharmacol, vol.171, pp.2080-90, 2014.

G. Aubert, O. J. Martin, and J. L. Horton, The failing heart relies on ketone bodies as a fuel, Circulation, vol.133, pp.698-705, 2016.

J. S. Jaswal, W. Keung, and W. Wang, Targeting fatty acid and carbohydrate oxidation: a novel therapeutic intervention in the ischemic and failing heart, Biochim Biophys Acta, vol.1813, pp.1333-50, 2011.

E. Ferrannini, M. Mark, and E. Mayoux, CV protection in the EMPA-REG OUTCOME trial: a Thrifty Substrate hypothesis, Diabetes care, vol.39, pp.1108-1122, 2016.

S. Mudaliar, S. Alloju, and R. R. Henry, Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis, Diabetes care, vol.39, pp.1115-1137, 2016.

J. P. Bonnefont, J. Bastin, and P. Laforet, Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency, Clin Pharmacol Ther, vol.88, pp.101-109, 2010.

P. J. Tire?s-À and . Bastin,